Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T
Department of Internal Medicine, Awaji-Hokudan Pubic Clinic, Japan.
Arterioscler Thromb Vasc Biol. 1995 Aug;15(8):1114-20. doi: 10.1161/01.atv.15.8.1114.
We studied the relationships between albuminuria, tissue factor-induced coagulation, and endothelial cell dysfunction in 67 patients with non-insulin-dependent diabetes mellitus (NIDDM) who were divided into three groups on the basis of their urinary albumin excretion rate (AER). To assess the early phase of tissue factor-induced coagulation, activated factor VII (FVIIa) levels in plasma were measured by a direct fluorogenic assay. As markers of endothelial cell dysfunction, levels of von Willebrand factor (vWF), tissue-type plasminogen activator-plasminogen activator inhibitor-1 (TPA-PAI-1) complex, PAI-1, and tissue factor pathway inhibitor (TFPI) were measured. FVIIa levels were increased in normoalbuminuric NIDDM patients (AER < 15 micrograms/min) when compared with normal control subjects. This FVIIa increase was accompanied by an increase in thrombin-antithrombin III complex (TAT) levels, indicating increased activation of coagulation even in normoalbuminuric patients. In NIDDM patients with microalbuminuria (AER = 15-200 micrograms/min), the FVIIa level, the FVIIa-FVII antigen (Ag) ratio (an indicator of activation of FVII zymogen to FVIIa), and the TAT level were further increased. This group also had higher levels of endothelial cell-derived factors (vWF, TPA-PAI-1 complex, and PAI-1) than the control group. The levels of endothelial cell-derived factors (including TFPI) were highest in the NIDDM patients with overt albuminuria (AER > 200 micrograms/min). In all 67 diabetic patients, AER showed a strong positive correlation with FVIIa (r = .574, P < .0001) and a weakly but still significant correlation with FVIIa-FVII:Ag (r = .365, P = .01), vWF (r = .315, P < .01), and TAT (r = .323, P < .01).(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了67例非胰岛素依赖型糖尿病(NIDDM)患者的蛋白尿、组织因子诱导的凝血和内皮细胞功能障碍之间的关系。这些患者根据尿白蛋白排泄率(AER)分为三组。为评估组织因子诱导凝血的早期阶段,通过直接荧光测定法测量血浆中活化因子VII(FVIIa)水平。作为内皮细胞功能障碍的标志物,测量血管性血友病因子(vWF)、组织型纤溶酶原激活物-纤溶酶原激活物抑制剂-1(TPA-PAI-1)复合物、PAI-1和组织因子途径抑制剂(TFPI)的水平。与正常对照受试者相比,正常白蛋白尿的NIDDM患者(AER<15微克/分钟)的FVIIa水平升高。FVIIa的这种升高伴随着凝血酶-抗凝血酶III复合物(TAT)水平的升高,表明即使在正常白蛋白尿患者中凝血激活也增加。在微量白蛋白尿的NIDDM患者(AER = 15-200微克/分钟)中,FVIIa水平、FVIIa-FVII抗原(Ag)比率(FVII酶原激活为FVIIa的指标)和TAT水平进一步升高。该组的内皮细胞衍生因子(vWF、TPA-PAI-1复合物和PAI-1)水平也高于对照组。在显性白蛋白尿的NIDDM患者(AER>200微克/分钟)中,内皮细胞衍生因子(包括TFPI)的水平最高。在所有67例糖尿病患者中,AER与FVIIa呈强正相关(r = 0.574,P < 0.0001),与FVIIa-FVII:Ag(r = 0.365,P = 0.01)、vWF(r = 0.315,P < 0.01)和TAT(r = 0.323,P < 0.01)呈弱但仍显著的相关。(摘要截短于250字)